FAB vs. OKYO, AOR, AREC, OPTI, POLB, SAR, IMM, RLM, NSCI, and OBD
Should you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include OKYO Pharma (OKYO), AorTech International (AOR), Arecor Therapeutics (AREC), OptiBiotix Health (OPTI), Poolbeg Pharma (POLB), Sareum (SAR), ImmuPharma (IMM), Realm Therapeutics (RLM), NetScientific (NSCI), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry.
Fusion Antibodies vs.
Fusion Antibodies (LON:FAB) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.
Fusion Antibodies received 47 more outperform votes than OKYO Pharma when rated by MarketBeat users. Likewise, 68.35% of users gave Fusion Antibodies an outperform vote while only 63.64% of users gave OKYO Pharma an outperform vote.
OKYO Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -137.11% beat OKYO Pharma's return on equity.
In the previous week, Fusion Antibodies had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for OKYO Pharma. Fusion Antibodies' average media sentiment score of 0.61 beat OKYO Pharma's score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the media.
21.0% of Fusion Antibodies shares are held by institutional investors. 11.4% of Fusion Antibodies shares are held by company insiders. Comparatively, 31.9% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Fusion Antibodies has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500.
Fusion Antibodies has higher revenue and earnings than OKYO Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Fusion Antibodies beats OKYO Pharma on 11 of the 14 factors compared between the two stocks.
Get Fusion Antibodies News Delivered to You Automatically
Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Antibodies Competitors List
Related Companies and Tools
This page (LON:FAB) was last updated on 3/31/2025 by MarketBeat.com Staff
